Reviewed by Michael Gill, B. Sc.
13 Celiac Disease Clinical Trials Near Me
Top Hospitals for Celiac Disease Clinical Trials
Image of Beth Israel Deaconess Medical Center in Massachusetts.
Beth Israel Deaconess Medical Center
Boston
2Active Trials
9All Time Trials for Celiac Disease
2009First Celiac Disease Trial
Image of Diablo Clinical Research in California.
Diablo Clinical Research
Walnut Creek
2Active Trials
3All Time Trials for Celiac Disease
2018First Celiac Disease Trial
Top Cities for Celiac Disease Clinical Trials
Image of Boston in Massachusetts.
Boston
5Active Trials
Beth Israel Deaconess Medical CenterTop Active Site
Image of Chesterfield in Michigan.
Chesterfield
4Active Trials
Clinical Research Institute of Michigan, LLCTop Active Site
Celiac Disease Clinical Trials by Phase of Trial
Phase < 1 Celiac Disease Clinical Trials
1Active Celiac Disease Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Celiac Disease Clinical Trials by Age Group
Most Recent Celiac Disease Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Celiac Disease Clinical Trials
Treatment Name
Active Celiac Disease Clinical Trials
All Time Trials for Celiac Disease
First Recorded Celiac Disease Trial
Group 3 in Part B
1
1
2022
Bovine colostrum
1
1
2022
DONQ52
1
1
2022
TAK-062
1
1
2022
Gluten Powder
1
2
2020
Recently Completed Studies with FDA Approved Treatments for Celiac Disease
Treatment
Year
Sponsor
PTG-100
2021
Nielsen Fernandez-Becker

What Are Celiac-Disease Clinical Trials?

Celiac disease is a disease that involves an immune reaction to eating gluten. As a result, those with celiac disease often suffer from various symptoms, including fatigue, weight loss, bloating, and malabsorption of vitamins and minerals.

Over time celiac disease can have severe complications, and the immune reaction to gluten can damage the small intestine.

According to Mayo Clinic, there is currently no cure for those with celiac disease, but patients can reduce symptoms by following a strict gluten-free diet.

Because there is no cure for celiac disease, clinical trials must be conducted to help those diagnosed with this condition.

Why Is Celiac Disease Being Studied Through Clinical Trials?

Currently, celiac disease cannot be cured, and those diagnosed can only eliminate gluten from their diet to help alleviate symptoms. Despite this, many celiac sufferers mistakenly ingest gluten or ingest food that has been cross-contaminated with gluten, which causes further organ damage to the small intestine.

It’s imperative that clinical trials are conducted to ease symptoms in those who have celiac disease and help improve their intestinal health.

Most people with celiac disease remain undiagnosed, but the NIH and experts estimate that 2 million people in the United States suffer from celiac disease.

What Are The Types Of Treatments Available For Celiac Disease?

There are currently no treatments for celiac disease besides following a strict gluten-free diet. However, in terms of clinical trials and research, there are a few treatments in the trial phases which could be used to treat celiac disease. These include:

  1. KAN -101. The KAN - 101 clinical trial aims to assess the safety and effectiveness of single and multiple doses of the KAN- 101 treatment for celiac disease.
  2. Larazotide Acetate. Larazotide Acetate is currently being trialed as a treatment to relieve symptoms in adults that have celiac disease.
  3. Antibody treatment. An antibody treatment is being tested to determine if it is an effective treatment for celiac disease. This clinical trial aims to help celiac patients who have not responded to or seen improvement in their condition by following a gluten-free diet.

What Are Some Recent Breakthrough Clinical Trials For Celiac Disease?

2021: ZED 1227 for the treatment of celiac disease – Dr. Detlef Shuppan has developed a new drug to treat gluten intolerance and celiac disease called ZED 1227. This may be the first and only effective treatment option for celiacs and is one of the only treatments where efficacy has been established.

2022: KAN - 101 – The drug KAN – 101 focuses on restoring the immune system's tolerance to gluten by targeting receptors in the liver. This clinical trial showed promising results after the first phase of testing and has been proven safe and well tolerated by the participants involved in the clinical trial.

Who Are Some Of The Key Opinion Leaders / Researchers In Celiac-Disease Clinical Trials?

Benjamin Lebwohl is the director at the Celiac Disease Center at Columbia University. Lebwohl and other researchers at the Celiac Disease Center have ongoing clinical research programs and trials for the treatment of celiac disease.

Dr. Alessio Fasano is the director at the Center for Celiac Research at Massachusetts General Hospital. Dr. Fasano is currently leading research projects in gastrointestinal microbiota and environmental factors to establish why some people are predisposed to celiac disease.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Syage JA, Murray JA, Green PHR, Khosla C. Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet. Dig Dis Sci. 2017 Sep;62(9):2428-2432. doi: 10.1007/s10620-017-4687-7. Epub 2017 Jul 28. https://pubmed.ncbi.nlm.nih.gov/287552662 Murray JA, Kelly CP, Green PHR, Marcantonio A, Wu TT, Mäki M, Adelman DC; CeliAction Study Group of Investigators. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease. Gastroenterology. 2017 Mar;152(4):787-798.e2. doi: 10.1053/j.gastro.2016.11.004. Epub 2016 Nov 15. https://pubmed.ncbi.nlm.nih.gov/278641273 Tye-Din JA, Daveson AJM, Goldstein KE, Hand HL, Neff KM, Goel G, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group. Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Med. 2020 Nov 26;18(1):362. doi: 10.1186/s12916-020-01828-y. https://pubmed.ncbi.nlm.nih.gov/33239013